Kolexia
Fizazi Karim Oncologie médicale
Fizazi Karim
Oncologie médicale
Gustave-Roussy
Villejuif, France
1 K Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Métastase tumorale Tumeurs osseuses Tumeurs embryonnaires et germinales Carcinomes Tumeurs du testicule Cellules tumorales circulantes Néphrocarcinome

Collaborateurs

Voir plus
Loriot Yohann
Loriot Yohann
Gustave-Roussy, Villejuif, France
Massard Christophe
Massard Christophe
Gustave-Roussy, Villejuif, France
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France
Albiges Laurence
Albiges Laurence
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Bayer
13 collaboration(s)
Dernière en 2023
MSD
10 collaboration(s)
Dernière en 2023
Janssen
10 collaboration(s)
Dernière en 2023
Advanced Accelerator Applications
5 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Essai Clinique (pharmaand GmbH)   18 mars 2024
CheckMate 9KD: A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
Essai Clinique (BMS)   01 mars 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
The oncologist   23 février 2024
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Essai Clinique (Pfizer)   21 février 2024
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Essai Clinique (Pfizer)   19 février 2024
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
JCO clinical cancer informatics   19 février 2024
TALAPRO-2: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Essai Clinique (Pfizer)   15 février 2024
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors: A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Essai Clinique (Unicancer)   01 février 2024
Design Considerations in the PSMAfore Trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine   01 février 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nature medicine   31 janvier 2024